Only 27% of patients who received MDT-All initiated systemic therapy prior to polyprogression or death compared to 58% amongst patients who did not receive MDT-All, though this difference did not reach statistical significance.
← all excerpts
Patterns and kinetics of hepatocellular carcinoma relapse post-liver transplantation: oligorecurrence and role of local therapies.
1
—
—